The global next-generation sequencing (NGS) services market size was valued at USD 1.04 billion in 2017 and is projected to exhibit a CAGR of 13.6% during the forecast period. Next-generation sequencing technology is increasingly leveraged for both conventional and non-conventional applications to gain rapid and comprehensive insights at a genomic level. This is primarily due to continuous improvements in automation, ancillary protocols, services, and analytical solutions in this field. This, in turn, has provided healthy growth prospects for the implementation of NGS in clinical workflows.
Growing demand for robust sequencing-based diagnostics has resulted in the inception of new seq-technologies, ranging from high-throughput sequencers to portable units. This has fomented the trend of clinical NGS in recent times. For example, in March 2018, ARUP Laboratories and IDbyDNA, Inc. introduced Explify Respiratory, an NGS test for respiratory infections, to assist physicians in screening patients with pneumonia and other respiratory diseases.
The market leader, Illumina, has launched the Illumina Propel Certification Program (CSPro) to establish a partnership between the company and laboratories. In December 2013, GENEWIZ, Inc. received Illumina’s CSPro certification for NGS and became a member of the elite group of Illumina genomics service providers. Personalis is another provider that received the CSPro Certifications in May 2013.
Most service providers employ platforms from Illumina, PacBio, and Oxford Nanopore Technologies. They use these technologies in-house to serve their customers by delivering projects with high quality and within the shortest timelines. There are also some products that are no longer commercially available, such as products from 454 Life Sciences.
Some products are still under development, such as the SOLiD platform and Ion Torrent’s semiconductor sequencing. However, these products are not as widely accepted as those offered by Illumina. In March 2017, Illumina launched a new flagship product NovaSeq 6000, which can produce 3 to 48 human genomes per run.
Data generated through genome sequencing is considered an efficient diagnostic and prognostic tool to aid clinicians in identifying specific characteristics in each patient. This, in turn, helps in offering personalized therapies to patients, thus improving patient outcomes. This factor is anticipated to fuel demand for NGS-based diagnostics in the coming years.
Some of the major issues faced by end users in the NGS services market are implementing large-scale data analysis and analytical challenges while conducting single-cell seq. Nevertheless, manufacturers are constantly strategizing their R&D in order to address these challenges and augment the scope of NGS services.
NGS-based human genome sequencing is the most widely offered and practiced segment and hence dominated the market with respect to revenue. In addition, the presence of a substantial number of key players in this segment attributed to its large share in 2017. Companies operating in this segment include BGI-Complete Genomics, Veritas Genetics, Macrogen, Full genomes.com, Novogene, SureGenomics, Partners LMM, Genos, BGI, 14 labs, Gene-by-Gene, and Personalis.
In January 2017, Illumina announced that it will be launching a new platform to sequence whole genome sequencing for USD 100. These initiatives by the market leader are anticipated to drive segment growth significantly.
On the other hand, gene regulation services are estimated to exhibit a lucrative CAGR during the forecast period. It covers small RNA sequencing, ChIP sequencing, lncRNA seq, isoform sequencing, and bisulfite sequencing. Various advantages offered by RNA sequencing have enabled the replacement of microarrays in many applications. It is expected that the application of RNA-seq will continue to expand over the coming years, thus driving segment growth at a rapid pace.
NGS services offered in the market include various aspects of sequencing, ranging from consultation to final result derivation. Some companies offer thorough protocol while others are engaged in offering standalone services to customers that have a lab equipped with NGS facilities but seek to outsource some portions of NGS workflow.
Sequencing services accounted for the dominant share in the next-generation sequencing services market in terms of revenue owing to the high cost of instruments. Companies have been offering a broad portfolio for a wide spectrum of sample types. For example, Novogene Corporation conducts sequencing and generates publication-ready data for the success of research programs of customers from various domains such as agricultural, biomedical, and environmental science.
Analysis of NGS data poses great challenges for researchers engaged in conducting sequencing protocols for their projects. This is because a systematic and intelligent methodology is required for efficient processing and interpretation of data. As there is an increase in the number of sequenced reads per run, the subsequent growth in demand for robust data management solutions is projected.
Universities and other research entities are considered as major end users in this market owing to the fact that currently, NGS is primarily being used for research purposes. Research entities are utilizing sequencing services to improve the outcomes of their projects and gain in-depth insights into the mechanism of disease occurrence.
However, with the rising trend of clinical NGS, hospitals, and clinics are projected to witness the fastest growth over the forecast period. This trend in clinical settings is marked by the growing implementation of NGS technology for the detection of fetal aneuploidies through analyzing fetal cfDNA obtained from a single maternal blood draw in prenatal diagnostic procedures.
In addition to this, the liquid biopsy NGS panel is receiving great attention among healthcare entities, including clinics and hospitals, for cancer management. The definition of a proper regulatory framework for the use of NGS in clinical settings is expected to support projected growth.
North America accounted for the largest share owing to factors such as well-established informatics network, effective regulatory guidelines pertaining to approval and usage of genetic tests, and the presence of market leaders in the region. In addition, growing number of FDA-approved genomic tests in the U.S. is anticipated to drive the regional market throughout the forecast period.
The Asia Pacific market is expected to serve as a lucrative source of revenue through 2025. The growing attention of government bodies toward the maintenance of public health and consequent investments in the development of advanced diagnostic approaches is anticipated to spur the uptake of seq-services in the region.
Furthermore, domestic players in Asian countries are involved in forming mutually beneficial partnerships among each other as well as with global companies for the establishment of NGS service providers. For instance, in 2017, Novogene China collaborated with Singapore-based AITbiotech to establish NovogeneAIT Genomics Singapore Pte Ltd., aimed at offering sequencing services in Southeast Asia.
Some of the key companies operating in this market are Illumina, Inc.; Veritas Genetics; BGI; GENEWIZ Germany GmbH; ABM Inc.; ARUP Laboratories; Novogene Corporation; Lucigen; Quest Diagnostics; and Gene by Gene.
These participants have collaborated with several platform manufacturers to receive a license for use of NGS at their centers. Furthermore, manufacturers are undertaking various marketing strategies to capitalize on avenues in untapped markets such as India, Brazil, and China.
For instance, in January 2018, Illumina introduced its BaseSpace Sequence Hub in China. This hub is a cloud-based solution launched for storage, management, and interpretation of genomic data. This will help accelerate start-up operations and upgrade existing operations in terms of sequencing volume and efficiency.
Base year for estimation
Actual estimates/Historical data
2014 - 2016
2018 - 2025
Revenue in USD Million and CAGR from 2018 to 2025
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
U.S., Canada, Germany, U.K., Japan, China, Brazil, South Africa
Revenue forecast, company share, competitive landscape, growth factors and trends
15% free customization scope (equivalent to 5-analyst working days)
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global next-generation sequencing services market on the basis of service type, workflow, end use, and region:
Service Type Outlook (Revenue, USD Million, 2014 - 2025)
Human Genome Sequencing
Single Cell Sequencing
Microbial Genome-based Sequencing
Gene Regulation Services
Small RNA Sequencing
Other Gene Regulation-based Services
Animal & Plant Sequencing
Other Sequencing Services
Workflow Outlook (Revenue, USD Million, 2014 - 2025)
End-use Outlook (Revenue, USD Million, 2014 - 2025)
Universities & Other Research Entities
Hospitals & Clinics
Pharma & Biotech Entities
Regional Outlook (Revenue, USD Million, 2014 - 2025)
Middle East & Africa
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.